Measles-derived vaccines to prevent emerging viral diseases

Microbes and Infection

Volumn 20, Issue 9-10, 2018, Pages 493-500

  Frantz, Phanramphoei N ^a,b   Teeravechyan, Samaporn ^b   Tangy, Frédéric ^a  

^a CNRS   (France)

^b NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

Author keywords

Emerging diseases; Measles vector; Vaccines

Indexed keywords

MEASLES VACCINE; RECOMBINANT VACCINE; VIRUS VACCINE; LIVE VACCINE;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG SAFETY; EPIDEMIC; GLOBAL HEALTH; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; NONHUMAN; PRIORITY JOURNAL; SEVERE ACUTE RESPIRATORY SYNDROME; SYSTEMATIC REVIEW; VACCINATION; VACCINE IMMUNOGENICITY; VIRUS ATTENUATION; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TRANSFORMATION; VULNERABLE POPULATION; ANIMAL; COMMUNICABLE DISEASE; GENE VECTOR; GENETICS; IMMUNOLOGY; VIRUS;

ANIMALS; COMMUNICABLE DISEASES, EMERGING; GENETIC VECTORS; HUMANS; MEASLES VACCINE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES; VIRUS DISEASES; VIRUSES;

EID: 85044618250     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2018.01.005     Document Type: Article

References (72)

1. Towards a one health approach for controlling zoonotic diseases, 2010, World Bank, Washington, D.C http://documents.worldbank.org/curated/en/214701468338937565/Volume-one-towards-a-one-health-approach-for-controlling-zoonotic-diseases.
2. The economic impact of the 2014 Ebola epidemic, Short and medium term estimates for West Africa. 2014, World Bank http://documents.worldbank.org.
3. Annual review of the list of priority diseases for the WHO R&D Blueprint. WH organization, 2017 http://www.who.int.
4. Zika situation report. WH organization, 2017 http://www.who.int.
5. Duc, J.W.L., Nathanson, N., Emerging viral diseases. Katze, M., Korth, M.J., Law, G.L., Nathanson, N., (eds.) Viral pathogenesis: from basics to systems biology, 2016, Academic Press, 215–231.
6. Ali, R., Mounts, A.W., Parashar, U.D., Sahani, M., Lye, M.S., Isa, M.M., et al. Nipah virus among military personnel involved in pig culling during an outbreak of encephalitis in Malaysia, 1998–1999. Emerg Infect Dis 7 (2001), 759–761.
7. Rewar, S., Mirdha, D., Transmission of ebola virus disease: an overview. Ann Glob Health 80 (2014), 444–451.
8. Kieny, M.P., Rottingen, J.A., Farrar, J., Who, R., team DB, Group DBSA. The need for global R&D coordination for infectious diseases with epidemic potential. Lancet 388 (2016), 460–461.
9. Jahrling, P.B., Geisbert, J.B., Swearengen, J.R., Larsen, T., Geisbert, T.W., Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 196:Suppl 2 (2007), S400–S403.
10. Guillaume, V., Contamin, H., Loth, P., Georges-Courbot, M.C., Lefeuvre, A., Marianneau, P., et al. Nipah virus: vaccination and passive protection studies in a hamster model. J Virol 78 (2004), 834–840.
11. Broder, C.C., Xu, K., Nikolov, D.B., Zhu, Z., Dimitrov, D.S., Middleton, D., et al. A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antiviral Res 100 (2013), 8–13.
12. Jegouic, S., Joffret, M.L., Blanchard, C., Riquet, F.B., Perret, C., Pelletier, I., et al. Recombination between polioviruses and co-circulating Coxsackie A viruses: role in the emergence of pathogenic vaccine-derived polioviruses. PLoS Pathog, 5, 2009, e1000412.
13. Calain, P., Roux, L., The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 67 (1993), 4822–4830.
14. Tangy, F., Naim, H.Y., Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol 18 (2005), 317–326.
15. Lorin, C., Mollet, L., Delebecque, F., Combredet, C., Hurtrel, B., Charneau, P., et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 78 (2004), 146–157.
16. Stebbings, R., Fevrier, M., Li, B., Lorin, C., Koutsoukos, M., Mee, E., et al. Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine. PLoS One, 7, 2012, e50397.
17. Stebbings, R., Li, B., Lorin, C., Koutsoukos, M., Fevrier, M., Mee, E.T., et al. Immunogenicity of a recombinant measles HIV-1 subtype C vaccine. Vaccine 31 (2013), 6079–6086.
18. Malczyk, A.H., Kupke, A., Prufer, S., Scheuplein, V.A., Hutzler, S., Kreuz, D., et al. A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J Virol 89 (2015), 11654–11667.
19. Radecke, F., Spielhofer, P., Schneider, H., Kaelin, K., Huber, M., Dotsch, C., et al. Rescue of measles viruses from cloned DNA. EMBO J 14 (1995), 5773–5784.
20. Combredet, C., Labrousse, V., Mollet, L., Lorin, C., Delebecque, F., Hurtrel, B., et al. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 77 (2003), 11546–11554.
21. Brandler, S., Ruffie, C., Combredet, C., Brault, J.B., Najburg, V., Prevost, M.C., et al. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 31 (2013), 3718–3725.
22. Ramsauer, K., Schwameis, M., Firbas, C., Mullner, M., Putnak, R.J., Thomas, S.J., et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 15 (2015), 519–527.
23. Mura, M., Combredet, C., Najburg, V., Sanchez David, R.Y., Tangy, F., Komarova, A.V., Nonencapsidated 5' copy-back defective interfering genomes produced by recombinant measles viruses are recognized by RIG-I and LGP2 but not MDA5. J Virol, 2017, 91 e00643-17.
24. Lorin, C., Combredet, C., Labrousse, V., Mollet, L., Despres, P., Tangy, F., A paediatric vaccination vector based on live attenuated measles vaccine. Therapie 60 (2005), 227–233.
25. Guerbois, M., Moris, A., Combredet, C., Najburg, V., Ruffie, C., Fevrier, M., et al. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. Virology 388 (2009), 191–203.
26. Lorin, C., Segal, L., Mols, J., Morelle, D., Bourguignon, P., Rovira, O., et al. Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques. Naunyn-Schmiedeberg's Arch Pharmacol 385 (2012), 1211–1225.
27. Liniger, M., Zuniga, A., Morin, T.N., Combardiere, B., Marty, R., Wiegand, M., et al. Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses. Vaccine 27 (2009), 3299–3305.
28. Zuniga, A., Liniger, M., Morin, T.N., Marty, R.R., Wiegand, M., Ilter, O., et al. Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector. Hum Vaccines Immunother 9 (2013), 607–613.
29. Despres, P., Combredet, C., Frenkiel, M.P., Lorin, C., Brahic, M., Tangy, F., Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 191 (2005), 207–214.
30. Brandler, S., Marianneau, P., Loth, P., Lacote, S., Combredet, C., Frenkiel, M.P., et al. Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection. J Infect Dis 206 (2012), 212–219.
31. Brandler, S., Lucas-Hourani, M., Moris, A., Frenkiel, M.P., Combredet, C., Fevrier, M., et al. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Neglected Trop Dis, 1, 2007, e96.
32. Brandler, S., Ruffie, C., Najburg, V., Frenkiel, M.P., Bedouelle, H., Despres, P., et al. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 28 (2010), 6730–6739.
33. del Valle, J.R., Devaux, P., Hodge, G., Wegner, N.J., McChesney, M.B., Cattaneo, R., A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol 81 (2007), 10597–10605.
34. Cantarella, G., Liniger, M., Zuniga, A., Schiller, J.T., Billeter, M., Naim, H.Y., et al. Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 27 (2009), 3385–3390.
35. Yoneda, M., Georges-Courbot, M.C., Ikeda, F., Ishii, M., Nagata, N., Jacquot, F., et al. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge. PLoS One, 8, 2013, e58414.
36. Yamaji, Y., Nakayama, T., Recombinant measles viruses expressing respiratory syncytial virus proteins induced virus-specific CTL responses in cotton rats. Vaccine 32 (2014), 4529–4536.
37. Escriou, N., Callendret, B., Lorin, V., Combredet, C., Marianneau, P., Fevrier, M., et al. Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Virology 452–453 (2014), 32–41.
38. Simmons, C.P., Farrar, J.J., Nguyen, vV, Wills, B., Dengue. N Engl J Med 366 (2012), 1423–1432.
39. Guzman, M.G., Alvarez, M., Halstead, S.B., Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 158 (2013), 1445–1459.
40. Osorio, J.E., Partidos, C.D., Wallace, D., Stinchcomb, D.T., Development of a recombinant, chimeric tetravalent dengue vaccine candidate. Vaccine 33 (2015), 7112–7120.
41. Buathong, R., Hermann, L., Thaisomboonsuk, B., Rutvisuttinunt, W., Klungthong, C., Chinnawirotpisan, P., et al. Detection of zika virus Infection in Thailand, 2012-2014. Am J Trop Med Hyg 93 (2015), 380–383.
42. Screaton, G., Mongkolsapaya, J., Yacoub, S., Roberts, C., New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol 15 (2015), 745–759.
43. Dick, G.W., Kitchen, S.F., Haddow, A.J., Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 46 (1952), 509–520.
44. Musso, D., Gubler, D.J., Zika virus. Clin Microbiol Rev 29 (2016), 487–524.
45. Teixeira, M.G., Costa Mda, C., de Oliveira, W.K., Nunes, M.L., Rodrigues, L.C., The epidemic of zika virus-related microcephaly in Brazil: detection, control, etiology, and future scenarios. Am J Publ Health 106 (2016), 601–605.
46. Musso, D., Roche, C., Robin, E., Nhan, T., Teissier, A., Cao-Lormeau, V.M., Potential sexual transmission of Zika virus. Emerg Infect Dis 21 (2015), 359–361.
47. Vouga, M., Musso, D., Van Mieghem, T., Baud, D., CDC guidelines for pregnant women during the Zika virus outbreak. Lancet 387 (2016), 843–844.
48. Dejnirattisai, W., Supasa, P., Wongwiwat, W., Rouvinski, A., Barba-Spaeth, G., Duangchinda, T., et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol 17 (2016), 1102–1108.
49. Li, W., Wong, S.K., Li, F., Kuhn, J.H., Huang, I.C., Choe, H., et al. Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. J Virol 80 (2006), 4211–4219.
50. Ki, M., 2015 MERS outbreak in Korea: hospital-to-hospital transmission. Epidemiol Health, 37, 2015, e2015033.
51. Liniger, M., Zuniga, A., Tamin, A., Azzouz-Morin, T.N., Knuchel, M., Marty, R.R., et al. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine 26 (2008), 2164–2174.
52. Kanapathipillai, R., Henao Restrepo, A.M., Fast, P., Wood, D., Dye, C., Kieny, M.P., et al. Ebola vaccine–an urgent international priority. N Engl J Med 371 (2014), 2249–2251.
53. Geisbert, T.W., Daddario-Dicaprio, K.M., Geisbert, J.B., Reed, D.S., Feldmann, F., Grolla, A., et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26 (2008), 6894–6900.
54. Geisbert, T.W., Daddario-Dicaprio, K.M., Lewis, M.G., Geisbert, J.B., Grolla, A., Leung, A., et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog, 4, 2008, e1000225.
55. Rezza, G., A vaccine against Ebola: problems and opportunities. Hum Vaccines Immunother 11 (2015), 1258–1260.
56. Henao-Restrepo, A.M., Camacho, A., Longini, I.M., Watson, C.H., Edmunds, W.J., Egger, M., et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 389 (2017), 505–518.
57. Henao-Restrepo, A.M., Longini, I.M., Egger, M., Dean, N.E., Edmunds, W.J., Camacho, A., et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386 (2015), 857–866.
58. Ewer, K., Rampling, T., Venkatraman, N., Bowyer, G., Wright, D., Lambe, T., et al. A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA. N Engl J Med 374 (2016), 1635–1646.
59. Bradfute, S.B., Warfield, K.L., Bavari, S., Functional CD8+ T cell responses in lethal Ebola virus infection. J Immunol 180 (2008), 4058–4066.
60. Geisbert, T.W., Jones, S., Fritz, E.A., Shurtleff, A.C., Geisbert, J.B., Liebscher, R., et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med, 2, 2005, e183.
61. Fisher-Hoch, S.P., McCormick, J.B., Auperin, D., Brown, B.G., Castor, M., Perez, G., et al. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc Natl Acad Sci U S A 86 (1989), 317–321.
62. Bredenbeek, P.J., Molenkamp, R., Spaan, W.J., Deubel, V., Marianneau, P., Salvato, M.S., et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345 (2006), 299–304.
63. Rahman, M.A., Hossain, M.J., Sultana, S., Homaira, N., Khan, S.U., Rahman, M., et al. Date palm sap linked to Nipah virus outbreak in Bangladesh. Vector Borne Zoonotic Dis 2012:12 (2008), 65–72.
64. Homaira, N., Rahman, M., Hossain, M.J., Epstein, J.H., Sultana, R., Khan, M.S., et al. Nipah virus outbreak with person-to-person transmission in a district of Bangladesh. Epidemiol Infect 2010:138 (2007), 1630–1636.
65. Weingartl, H.M., Berhane, Y., Caswell, J.L., Loosmore, S., Audonnet, J.C., Roth, J.A., et al. Recombinant nipah virus vaccines protect pigs against challenge. J Virol 80 (2006), 7929–7938.
66. Mire, C.E., Versteeg, K.M., Cross, R.W., Agans, K.N., Fenton, K.A., Whitt, M.A., et al. Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease. Virol J, 10, 2013, 353.
67. Lo, M.K., Bird, B.H., Chattopadhyay, A., Drew, C.P., Martin, B.E., Coleman, J.D., et al. Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antiviral Res 101 (2014), 26–29.
68. Prescott, J., DeBuysscher, B.L., Feldmann, F., Gardner, D.J., Haddock, E., Martellaro, C., et al. Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease. Vaccine 33 (2015), 2823–2829.
69. Faburay, B., Lebedev, M., McVey, D.S., Wilson, W., Morozov, I., Young, A., et al. A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep. Vector Borne Zoonotic Dis 14 (2014), 746–756.
70. Faburay, B., LaBeaud, A.D., McVey, D.S., Wilson, W.C., Richt, J.A., Current status of Rift Valley fever vaccine development. 2017, Vaccines, Basel, 5.
71. Randall, R., Gibbs, C.J. Jr., Aulisio, C.G., Binn, L.N., Harrison, V.R., The development of a formalin-killed Rift Valley fever virus vaccine for use in man. J Immunol 89 (1962), 660–671.
72. Harrington, D.G., Lupton, H.W., Crabbs, C.L., Peters, C.J., Reynolds, J.A., Slone, T.W. Jr., Evaluation of a formalin-inactivated Rift Valley fever vaccine in sheep. Am J Vet Res 41 (1980), 1559–1564.